Utah Medical Products Inc (NASDAQ: UTMD)

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0000706698
Market Cap 230.13 Mn
P/B 2.59
P/E 12.40
P/S 5.48
ROIC (Qtr) 8.00
Div Yield % 2.71
Rev 1y % (Qtr) -1.93
Total Debt (Qtr) 241,000.00
Debt/Equity (Qtr) 0.00

About

Utah Medical Products, Inc., or UTMD, is a medical device company that has made a name for itself by producing high-quality, cost-effective medical devices since its inception in 1978. UTMD's products are primarily used in critical care areas such as neonatal intensive care units (NICUs), labor and delivery departments, and women's health centers. These devices are designed to improve patient outcomes and reduce the risk of complications associated with medical procedures. UTMD operates in the medical device industry, with its products being used...

Read more

Price action

Investment thesis

Bull case

  • Strong operating cash flow of 14.15M provides robust 58.72x coverage of total debt 241000, indicating excellent debt servicing capability and financial flexibility.
  • Strong tangible asset base of 106.53M provides 442.04x coverage of total debt 241000, indicating robust asset backing and low credit risk.
  • Operating cash flow of 14.15M provides strong 42.24x coverage of stock compensation 335000, indicating sustainable incentive practices.
  • Robust free cash flow of 13.88M exceeds capital expenditure of 271000 by 51.22x, indicating strong organic growth funding capability.
  • Retained earnings of 127.96M provide full 530.95x coverage of long-term debt 241000, indicating strong internal capital position.

Bear case

  • Operating cash flow of 14.15M barely covers its investment activities of (271000), with a coverage ratio of -52.22, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (271000) provide weak support for R&D spending of 577000, which is -0.47x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of 14.15M provides thin coverage of dividend payments of (4.04M) with a -3.50 ratio, suggesting potential dividend sustainability issues if operational performance deteriorates.
  • Retained earnings of 127.96M provide limited buffer against comprehensive income items of (9.74M), which is -13.14x, indicating elevated exposure to market risks.
  • R&D investment of 577000 represents just 0.06x of SG&A expenses of 9.59M, indicating potential underinvestment in innovation relative to administrative overhead.

Geographical Breakdown of Revenue (2024)

Geographical Breakdown of Revenue (2024)

Peer comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ISRG Intuitive Surgical Inc 174.27 Bn 61.02 17.31 0.00 Bn
2 BDX Becton Dickinson & Co 59.72 Bn 37.77 3.14 19.18 Bn
3 RMD Resmed Inc 39.76 Bn 26.76 7.37 0.85 Bn
4 ALC Alcon Inc 38.93 Bn 37.18 3.82 5.24 Bn
5 WST West Pharmaceutical Services Inc 17.69 Bn 133.13 12.54 0.30 Bn
6 HOLX Hologic Inc 16.81 Bn 30.91 4.07 2.52 Bn
7 COO Cooper Companies, Inc. 16.37 Bn 43.67 4.00 2.51 Bn
8 ALGN Align Technology Inc 13.73 Bn 36.29 3.45 0.09 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 1.48 2.75
EV to Cash from Ops. EV/CFO 10.74 39.87
EV to Debt EV to Debt 750.10 27.09
EV to EBIT EV/EBIT 9.29 32.86
EV to EBITDA EV/EBITDA 8.35 19.31
EV to Free Cash Flow [EV/FCF] EV/FCF 10.45 0.88
EV to Market Cap EV to Market Cap 0.79 -4.26
EV to Revenue EV/Rev 4.30 252.61
Price to Book Value [P/B] P/B 2.59 6.13
Price to Earnings [P/E] P/E 12.40 184.03
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 2.87 -1.09
Dividend Payout Ratio % Div Payout % (Qtr) 34.50 1.36
Dividend per Basic Share Div per Share (Qtr) 1.22 0.25
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 28.19 8.74
Interest Coverage Int. cover (Qtr) 0.00 -117.83
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 4.58 -53.47
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -4.73 414.02
Dividend Growth (1y) % Div 1y % (Qtr) 1.67 -1.48
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -23.83 -57.42
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -16.30 -106.89
EBIT Growth (1y) % EBIT 1y % (Qtr) -19.71 -37.00
EBT Growth (1y) % EBT 1y % (Qtr) -19.71 -42.63
EPS Growth (1y) % EPS 1y % (Qtr) -17.10 -15.05
FCF Growth (1y) % FCF 1y % (Qtr) -18.07 56.29
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) -14.89 67.95
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.32 0.54
Cash Payout Ratio Cash Payout (Qtr) 0.28 0.03
Cash Ratio Cash Ratio (Qtr) 27.99 2.51
Current Ratio Curr Ratio (Qtr) 32.06 7.80
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 0.55
Interest Cover Ratio Int Coverage (Qtr) 0.00 -117.83
Times Interest Earned Times Interest Earned (Qtr) 0.00 -117.83
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 45.50 -2,368.59
EBIT Margin % EBIT Margin % (Qtr) 37.84 -2,472.59
EBT Margin % EBT Margin % (Qtr) 37.84 -2,442.52
Gross Margin % Gross Margin % (Qtr) 57.10 30.06
Net Profit Margin % Net Margin % (Qtr) 30.10 -2,438.49